In mild to moderate AD
Reach for EUCRISA for patients under your care

EUCRISA is the first and only topical PDE-4 inhibitor indicated for the topical treatment of mild to moderate AD in patients 2 years of age and older.¹ ²

AD=atopic dermatitis; PDE-4=phosphodiesterase-4.  
* Comparative clinical significance unknown.
Significantly more patients achieved success in ISGA at Day 29 vs. vehicle (31.4% vs. 18%; \( p \leq 0.001 \))

Success in ISGA:
defined as score of CLEAR (0) or ALMOST CLEAR (1) and \( \geq 2 \)-grade improvement from baseline at Day 29

ISGA=Investigator's Static Global Assessment.

† Actual case. Individual results may vary. May not represent results for all patients. Adapted from Paller A, et al.
Proven safety and tolerability profile¹

4-WEEK PIVOTAL TRIALS

Adverse reactions occurring in ≥1% of patients in the 4-week pivotal trials

APPLICATION SITE PAIN§

4.45% (n=45) EUCRISA (N=1012)

1.20% (n=6) Proprietary vehicle ointment (N=499)

48-WEEK, OPEN-LABEL, SINGLE-ARM, LONG-TERM SAFETY STUDY¹

Most frequently reported adverse events in patients receiving EUCRISA intermittently (n=517) included:

- Atopic dermatitis
- Application site pain§
- Application site infection

Discontinuation rate due to adverse events was 2%.

§ Application site pain refers to skin sensations such as burning or stinging.
¹ 517 patients (including 454 patients aged 2–17 years) who completed the 28-day pivotal trials without safety issues that precluded further treatment were treated with EUCRISA intermittently for up to 48 weeks in 28-day on-treatment or off-treatment cycles.
Consider EUCRISA as part of your treatment plan for patients with mild to moderate AD

Apply thin layer topically twice daily
Ages 2 and up
Anywhere on affected skin

Relevant warnings and precautions
- Hypersensitivity reactions, including contact urticaria
- Use in pregnant and nursing women
- Use in geriatric patients

For more information
Consult the Product Monograph at http://pfizer.ca/pm/en/Eucrisa.pdf for information regarding adverse reactions, drug interactions, and dosing. The Product Monograph is also available by calling 1-800-463-6001.


Clinical significance unknown.